Susan Ashton

7.1k total citations
25 papers, 1.2k citations indexed

About

Susan Ashton is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Susan Ashton has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susan Ashton's work include Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Susan Ashton is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Susan Ashton collaborates with scholars based in United Kingdom, United States and Singapore. Susan Ashton's co-authors include Anderson J. Ryan, Andrew A. Godfrey, Andrew Barker, J.R. Woodburn, Keith H. Gibson, Mark P. Healy, Brenda J Curry, L. Scarlett, Laura M. Richards and David C. Blakey and has published in prestigious journals such as Nature Communications, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Susan Ashton

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Susan Ashton

Since Specialization

Citations

This map shows the geographic impact of Susan Ashton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Ashton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Ashton more than expected).

Fields of papers citing papers by Susan Ashton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Ashton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Ashton. The network helps show where Susan Ashton may publish in the future.

Co-authorship network of co-authors of Susan Ashton

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Ashton. A scholar is included among the top collaborators of Susan Ashton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Ashton. Susan Ashton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma 2019 ·Molecular Cancer Therapeutics ·Nicolas Floc’h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S. Carnevalli, Adina Hughes, Emily Harris, Maureen M. Hattersley, Shenghua Wen, Nicola J. Curtis, James Pilling, Lucy A. Young, (unknown), (unknown), Simon T. Barry	16
2	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance 2019 ·Nature Communications ·Matthew J. Sale, Kathryn Balmanno, (unknown), Eiko Ozono, Katarzyna Wojdyła, Rebecca E. McIntyre, Rebecca Gilley, (unknown), Karen Howarth, Gareth Hughes, Jonathan R. Dry, Mark J. Arends, Pilar Caro, David Oxley, Susan Ashton, David J. Adams, Julio Sáez-Rodríguez, Paul D. Smith, Simon J. Cook	41
3	Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles 2017 ·Molecular Cancer Therapeutics ·Nicolas Floc’h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris, Rajesh Odedra, (unknown), (unknown), (unknown), Vivien N. Jacobs, Maureen M. Hattersley, Shenghua Wen, Nicola J. Curtis, James Pilling, (unknown), Simon T. Barry	29
4	Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104 2016 ·Molecular Cancer Therapeutics ·James Yates, Susan Ashton, Darren A.E. Cross, Martine J. Mellor, Steve Powell, Peter Ballard	34
5	A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system 2016 ·Journal of Controlled Release ·Young Ho Song, (unknown), Hong Wang, James J. Nolan, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Susan Ashton, Marianne Ashford, Mir Mukkaram Ali, (unknown), Nicholas J. Boylan, Greg Troiano	73
6	Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation 2016 ·ACS Medicinal Chemistry Letters ·Edward J. Hennessy, Claudio Chuaqui, Susan Ashton, Nicola Colclough, Darren A.E. Cross, J.E. Debreczeni, Cath Eberlein, Lakshmaiah Gingipalli, Teresa Klinowska, Jonathan P. Orme, Sha Li, Xiaoyun Wu	7
7	Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma 2016 ·Oncotarget ·Matthew J. Martin, Cath Eberlein, Molly A. Taylor, Susan Ashton, David M. Robinson, Darren A.E. Cross	39
8	PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary 2015 ·Toxicologic Pathology ·Anthony Hall, Susan Ashton, (unknown), Zena Wilson, (unknown), Graham H.P. Richmond, Simon T. Barry, Stephen R. Wedge	10
9	Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291 2015 ·Cancer Research ·Celina M. D’Cruz, Evan Barry, Ryan E. Henry, Lillian Castriotta, Alwin G. Schuller, Garry Beran, Susan Ashton, Cath Eberlein, Corinne Reimer, Melanie M. Frigault, Michael Zinda, Darren A.E. Cross, Stephen E. Fawell	2
10	Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index 2014 ·Cancer Research ·Simon T. Barry, Elaine Cadogan, Rajesh Odedra, Susan Ashton, John R. Foster, Young Ho Song, Susan C. Low, Paula Taylor, Rebecca Ellston, Urszula M. Polanska, Joanne Wilson, Colin Howes, Dawn Trueman, Mike Walker, (unknown), Marianne Ashford, Jeff Hrkach, (unknown)	2
11	Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease. 2013 ·Cancer Research ·Gayle Marshall, Susan Ashton, Georgina Speake, Celina M. D’Cruz, Michael Grondine, Cath Trigwell, Graham Bigley, Garry Beran, (unknown), Teresa Klinowska	1
12	Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2‐specific antagonist is associated with reduced tumor growth 2011 ·International Journal of Cancer ·Simon Tazzyman, Simon T. Barry, Susan Ashton, Pauline J. Wood, David C. Blakey, Claire E. Lewis, Craig Murdoch	89
13	Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers 2010 ·Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Neil H. James, Kirsty Ratcliffe, Martin Jenkins, Susan Ashton, (unknown), Ruth Swann, Neil Gray, Anderson J. Ryan, Juliane M. Jürgensmeier, Chris Womack	197
14	Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats 2007 ·JNCI Journal of the National Cancer Institute ·(unknown), F. Russell Westwood, Jon Curwen, Susan Ashton, David W. Roberts, (unknown), Anderson J. Ryan	22
15	Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats 2007 ·Neoplasia ·Daniel P. Bradley, Jean Tessier, Susan Ashton, John C. Waterton, Zena Wilson, Philip Worthington, Anderson J. Ryan	25
16	Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126 2006 ·Microvascular Research ·(unknown), Tammy L. Kalber, Susan Ashton, Judith E. Cartwright, John R. Griffiths, Anderson J. Ryan, Simon P. Robinson	28
17	Aminoimidazolylmethyluracil Analogues as Potent Inhibitors of Thymidine Phosphorylase and Their Bioreductive Nitroimidazolyl Prodrugs 2004 ·Journal of Medicinal Chemistry ·Philip Reigan, Philip N. Edwards, Abdul M Gbaj, Christian Cole, Simon T. Barry, Ken Page, Susan Ashton, Richard Luke, Kenneth T. Douglas, Ian J. Stratford, Mohammed Jaffar, Richard A. Bryce, Sally Freeman	43
18	ZD6126: A novel small molecule vascular targeting agent 2002 ·International Journal of Radiation OncologyBiologyPhysics ·David C. Blakey, Susan Ashton, F. Russell Westwood, Mike Walker, Anderson J. Ryan	52
19	Urinary excretion of MHPG and normetanephrine in attention deficit hyperactivity disorder 1993 ·Molecular and Chemical Neuropathology ·Glen B. Baker, Robert A. Bornstein, Alan B. Douglass, (unknown), Susan Ashton, (unknown)	7
20	Tourism in Malta 1991 ·Scottish Geographical Magazine ·(unknown), Susan Ashton	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact